INNOVIVA, INC. Payments to Acquire Debt Securities, Available-for-sale
INNOVIVA, INC. (INVA) reported Payments to Acquire Debt Securities, Available-for-sale of $231.91 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-19.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2020-02-19
- INNOVIVA, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2019-12-31 was $993.00K, a 98.00% decline year-over-year.
- INNOVIVA, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2019-09-30 was $118.99M, a 3895.53% increase year-over-year.
- INNOVIVA, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2019-06-30 was $9.89M, a 28.94% decline year-over-year.
- INNOVIVA, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2019-03-31 was $102.04M, a 1803.06% increase year-over-year.
- INNOVIVA, INC. payments to acquire debt securities, available-for-sale for fiscal 2019 was $231.91M, a 222.75% increase from fiscal 2018.
- INNOVIVA, INC. payments to acquire debt securities, available-for-sale for fiscal 2018 was $71.86M, a 6.26% increase from fiscal 2017.
- INNOVIVA, INC. payments to acquire debt securities, available-for-sale for fiscal 2017 was $67.62M, a 29.35% decline from fiscal 2016.
- INNOVIVA, INC. payments to acquire debt securities, available-for-sale for fiscal 2016 was $95.72M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2019-12-31 | $993.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $119.98M derived: sum of 2 quarters · filed 2020-02-19 | $129.87M derived: sum of 3 quarters · filed 2020-02-19 | $231.91M 10-K · filed 2020-02-19 |
| 2019-09-30 | $118.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $128.88M derived: sum of 2 quarters · filed 2019-10-30 | $230.92M 10-Q · filed 2019-10-30 | $280.52M derived: sum of 4 quarters · filed 2020-02-19 |
| 2019-06-30 | $9.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $111.94M 10-Q · filed 2019-07-24 | $161.53M derived: sum of 3 quarters · filed 2020-02-19 | $164.51M derived: sum of 4 quarters · filed 2020-02-19 |
| 2019-03-31 | $102.04M 10-Q · filed 2019-05-01 | $151.64M derived: sum of 2 quarters · filed 2020-02-19 | $154.61M derived: sum of 3 quarters · filed 2020-02-19 | $168.54M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-12-31 | $49.59M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $52.57M derived: sum of 2 quarters · filed 2020-02-19 | $66.49M derived: sum of 3 quarters · filed 2020-02-19 | $71.86M 10-K · filed 2020-02-19 |
| 2018-09-30 | $2.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $16.90M derived: sum of 2 quarters · filed 2019-10-30 | $22.26M 10-Q · filed 2019-10-30 | $48.14M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | $13.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $19.28M 10-Q · filed 2019-07-24 | $45.16M derived: sum of 3 quarters · filed 2020-02-19 | $74.94M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | $5.36M 10-Q · filed 2019-05-01 | $31.24M derived: sum of 2 quarters · filed 2020-02-19 | $61.02M derived: sum of 3 quarters · filed 2020-02-19 | $68.99M derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | $25.88M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $55.65M derived: sum of 2 quarters · filed 2020-02-19 | $63.63M derived: sum of 3 quarters · filed 2020-02-19 | $67.62M 10-K · filed 2020-02-19 |
| 2017-09-30 | $29.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $37.75M derived: sum of 2 quarters · filed 2018-10-31 | $41.74M 10-Q · filed 2018-10-31 | |
| 2017-06-30 | $7.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $11.97M 10-Q · filed 2018-07-26 | ||
| 2017-03-31 | $3.99M 10-Q · filed 2018-05-04 | |||
| 2016-12-31 | $95.72M 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |